Evolent Health
EVH
152 hedge funds and large institutions have $1.13B invested in Evolent Health in 2018 Q1 according to their latest regulatory filings, with 25 funds opening new positions, 56 increasing their positions, 39 reducing their positions, and 27 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
44% more repeat investments, than reductions
Existing positions increased: 56 | Existing positions reduced: 39
20% more capital invested
Capital invested by funds: $940M → $1.13B (+$190M)
2.58% more ownership
Funds ownership: 103.51% → 106.09% (+2.6%)
6% more call options, than puts
Call options by funds: $1.49M | Put options by funds: $1.4M
7% less first-time investments, than exits
New positions opened: 25 | Existing positions closed: 27
3% less funds holding
Funds holding: 156 → 152 (-4)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of New York Mellon
New York
|
+$32.4M |
| 2 |
Capital Research Global Investors
Los Angeles,
California
|
+$14.7M |
| 3 |
Lazard Asset Management
New York
|
+$8.7M |
| 4 |
LCM
Laurion Capital Management
New York
|
+$8.58M |
| 5 |
ECP
Elk Creek Partners
Denver,
Colorado
|
+$5.22M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$14.7M |
| 2 |
William Blair & Company
Chicago,
Illinois
|
-$7.01M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$6.49M |
| 4 |
ACP
Acuta Capital Partners
Redwood City,
California
|
-$5.17M |
| 5 |
GIM
Granahan Investment Management
Waltham,
Massachusetts
|
-$4.48M |
EVH Hedge Fund Activity: Q1 2018 in Review
152 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in Evolent Health (EVH) for Q1 2018, worth a combined $1.13B — up 20% from $940M a quarter earlier.
Sellers outnumbered buyers: 27 funds closed out of EVH and 25 opened new positions — a net loss of 2 holders — while 39 trimmed existing stakes and 56 added.
The largest buyer was Bank of New York Mellon, adding an estimated $32.4M. The largest seller was Citadel Advisors, cutting an estimated $14.7M.
- 152 institutional investors held Evolent Health (EVH) as of Q1 2018, down from 156 in Q4 2017.
- Funds reported $1.13B of Evolent Health stock for Q1 2018, up 20% quarter-over-quarter.
- 25 funds opened new Evolent Health positions in Q1 2018 and 27 closed out, a net change of -2 holders.
- The largest Evolent Health buyer in Q1 2018 was Bank of New York Mellon, an estimated $32.4M added.
- The largest Evolent Health seller in Q1 2018 was Citadel Advisors, an estimated $14.7M sold.
Based on aggregated 13F filings for Q1 2018.